Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

  • New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials
  • Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation
  • The new programs build on a successful first year of the multi-million-dollar corporate initiative

Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on the partnerships, scholarships, and the focus on diversified participants in the company's own clinical trials during the initiative's first year.

The latest programs include the launch of a new initiative with the Norton Healthcare Foundation to build and implement new models of sustainable clinical research alongside the Institute for Health Equity, a Part of Norton Healthcare in Louisville, Ky. ; a new training program for clinical research coordinators in partnership with Barnett International; and a newly-created Diversity in Research Office at Abbott focused on ensuring diverse representation in clinical trials.

"Clinical trials drive new, innovative tools to fight diseases, and overcoming barriers to access to clinical trials for under-represented communities is critical to improving health equity," said Andrea Wainer , executive vice president, Rapid and Molecular Diagnostics, and co-executive sponsor for the company's Diversity in Clinical Trials steering committee alongside Lisa Earnhardt , executive vice president of Medical Devices at Abbott. "Abbott has been focused on breaking down barriers and implementing new, sustainable partnerships and programs to drive even more diversity in our clinical trials and to ensure trials are offered in more places to reach underserved areas."

Improving Access Through New Clinical Research Models
Through a new five-year commitment, Abbott will work alongside the Institute for Health Equity at Norton Healthcare to build research program models that can be implemented by historically black colleges and universities (HBCUs) and clinics serving under-represented communities so they don't need to design and develop their own research programs from the ground up, which can be expensive and resource intensive.

Within the program, Abbott and Norton Healthcare will provide a roadmap of best practices to help community-based clinics create clinical trial research centers of excellence. The initiative will also provide grants to support the hiring and training of research coordinators and data managers and help guide the launch of research programs. Alongside building sustainable research programs, the effort aims to increase the number of trial sites that can reach underserved populations to reduce barriers to clinical trials.

The first pilot project stemming from the new grant will work to better connect more people from underrepresented communities to clinical trials. The first project will develop a new research center in Louisville, Ky. , focused on helping more African American patients access clinical trial opportunities. The project will specifically support patients in historically redlined areas of Louisville . "Redlining" is a discriminatory practice of withholding services from neighborhoods with significant numbers of racial and ethnic minorities and low-income residents. As a result, those communities have had reduced access to health services, including clinical research opportunities.

"As we focus on improving access to innovative health care options for patients who have been historically under-represented in clinical research, developing new models for research centers that can be implemented within rural or urban community clinics can have a profound impact on improving access to clinical trials for these patients," said Kelly McCants , M.D., a heart failure cardiologist and executive director of the Norton Heart & Vascular Institute Advanced Heart Failure & Recovery Program, who will help launch one of the pilot programs.

Expanding the Pool of Diverse Clinical Research Coordinators
Clinical research coordinators within healthcare clinics, doctor's offices and hospitals are essential to the success of clinical trials. They are key to improving the diversity of clinical trials because they serve as a central point of contact for patients, their families and the investigating physician leading the clinical trial. Through a partnership with Barnett International, Abbott is providing a comprehensive education program to support the training of new coordinators who are from diverse backgrounds and who will work with under-represented communities.

Upon completion of this course, participants will have a strong foundation in essential core areas of conducting clinical research. This includes training on study execution, the patient consent process, Good Clinical Practice guidelines, source documentation requirements and other regulatory required procedures. Offering training to clinical research coordinators with diverse backgrounds will address another key barrier for potential study participants.

New Diversity in Research Office within Abbott
Alongside new external partnerships and programs, the company has established a Diversity in Research Office to further Abbott's focus on driving diversity in the company's clinical trials and improving access to care among under-represented populations.

The new Diversity in Research Office will be led by Jennifer Jones-McMeans , Ph.D., divisional vice president of global clinical affairs for Abbott's vascular business, and Aparna Ahuja , M.D., divisional vice president for medical, clinical, and scientific affairs, Infectious Disease, for Abbott's rapid diagnostics business. The office will be responsible for ensuring that research efforts include diversity plans, key performance goals and foster collaboration across Abbott, the industry and regulatory bodies.

"Ensuring that clinical trials are as diverse as the people a product intends to serve is critically important in providing the best health care, so we're developing programs to address as many barriers as possible," said Jones-McMeans. "At Abbott, we've implemented programs that will increase the diversity of trials, including assessing how we conduct our own trials to make sure that we're doing all we can do to increase diversity in our clinical trials by increasing participation from under-served and under-represented populations."

Building Sustainable Change
Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation.

In the first year of the program, Abbott established a Diversity in Clinical Trials Medical Advisory Board comprised of external experts, an internal steering committee and has focused on increasing diversity enrollment in the company's own clinical trials. Through $5 million in grants, the company also sponsored more than 300 scholarships at the four HBCU medical schools and the National Black Nurses Association and National Association of Hispanic Nurses to support future leaders of clinical research.

To learn more about Abbott's Diversity in Research Initiative, visit https://www.abbott.com/diversity-in-clinical-trials.html .

Innovating for Greater Access and Equity in Health
Abbott's work to drive diversity in medical research is one example of the company innovating for greater access and affordability in health, the key priority of Abbott's 2030 Sustainability Plan . Abbott's ongoing commitment to address health equity challenges also includes targeted programs to create opportunities in STEM for women and underrepresented groups, build a more diverse healthcare supply chain and empower communities to break down social and economic barriers to better health.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at https://www.facebook.com/Abbott and on Twitter @AbbottNews .

Cision View original content: https://www.prnewswire.com/news-releases/abbott-announces-new-partnerships-and-programs-to-advance-its-diversity-in-clinical-trials-initiative-301821930.html

SOURCE Abbott

News Provided by PR Newswire via QuoteMedia

ABT
The Conversation (0)
richard murray md

Avisa Diagnostics Appoints Dr. Richard Murray as Chief Medical Officer

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, is pleased to announce that the Company has hired Richard K. Murray, M.D., to the newly created position of Chief Medical Officer (CMO).

Dr. Murray has over 25 years of industry experience. He worked at Merck & Co. for many years in positions of increasing responsibility, in a variety of business, medical and scientific areas. His most recent position was Vice President and Deputy Chief Patient Officer. Dr. Murray was also a Fellow at the Advanced Leadership Initiative at Harvard University. He has managed all areas of medical affairs, including outcomes research, medical information, professional and academic affairs, field-based medical physicians, and investigator-initiated trials globally. Prior to his industry career, he was a practicing physician in cardiovascular-pulmonary medicine and an asthma researcher at the Hospital of the University of Pennsylvania. Dr. Murray has an M.D. from Howard University and an M.A. in Chemistry and A.B. in Psychology from Clark University. Dr. Murray currently is Board Chair of the Asthma and Allergy Foundation of America.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avisa Diagnostics Begins Trading on the Canadian Securities Exchange

Avisa Diagnostics Begins Trading on the Canadian Securities Exchange

  • Public Listing offers Access to CAD 52 Million from Share Subscription and Drawdown Agreement, Sufficient Funding to Complete Development and Launch Avisa BreathTest™
  • Pivotal Trials Planned in Post-COVID-19 Long Haulers and Ventilator-Associated Pneumonia

Avisa Diagnostics Inc. (Avisa) is pleased to announce that the Company has begun trading on the Canadian Securites Exchange (CSE:AVBT) through the previously announced merger completion with Fogchain Corp. Avisa has developed the Avisa BreathTest™ (ABT), an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in Post-COVID-19 “long haulers,” who can develop acute respiratory disease, and ventilator-associated pneumonia (VAP), an indication with high morbidity and mortality.

The public listing enables Avisa to draw down over the period of three years CAD 52 million (~USD 41 million) from a share subscription and drawdown agreement put in place in 2020 with GEM GLOBAL YIELD LLC SCS (GEM), a $3.4 billion alternative investment group with offices in Paris, New York, and Los Angeles.

Keep reading...Show less
abt stock

Avisa Diagnostics Begins Trading on the Canadian Securities Exchange

  • Public Listing offers Access to CAD 52 Million from Share Subscription and Drawdown Agreement, Sufficient Funding to Complete Development and Launch Avisa BreathTest™
  • Pivotal Trials Planned in Post-COVID-19 Long Haulers and Ventilator-Associated Pneumonia

Avisa Diagnostics Inc. (Avisa) is pleased to announce that the Company has begun trading on the Canadian Securites Exchange (CSE:AVBT) through the previously announced merger completion with Fogchain Corp. Avisa has developed the Avisa BreathTest™ (ABT), an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in Post-COVID-19 "long haulers," who can develop acute respiratory disease, and ventilator-associated pneumonia (VAP), an indication with high morbidity and mortality.

The public listing enables Avisa to draw down over the period of three years CAD 52 million (~USD 41 million) from a share subscription and drawdown agreement put in place in 2020 with GEM GLOBAL YIELD LLC SCS (GEM), a $3.4 billion alternative investment group with offices in Paris, New York, and Los Angeles.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Aehr Test Systems Receives Orders of Over $2.3 million

Aehr Test Systems (NASDAQ:AEHR) has over 2,500 systems installed over the world that test optical and memory integrated circuits, semiconductors and reliability qualification equipment announced that it received over $2.3 million in orders for test and burn-in services. These orders came from a major manufacturer where Aehr’s services would be implemented for automotive products.

As quoted in the press release:

Keep reading...Show less

Cyclacel Reports Fourth Quarter And 2016 Financial Results

Cyclacel Pharmaceuticals (NASDAQ:CYCC) posted its financial results for the fourth quarter and full year 2016.
As quoted in the press release:

The Company’s net loss applicable to common shareholders for the three months and year ended December 31, 2016 was $2.9 million and $12.0 million, respectively. As of December 31, 2016, cash and cash equivalents totaled $16.5 million.

Keep reading...Show less
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx for Recurrent Pericarditis

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx for Recurrent Pericarditis

Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis pain

CardiolRx™ also shown to reduce inflammation in patients with elevated CRP

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Mushrooms on cutting board with knife.

Functional Mushrooms: A Market Overview

Functional mushrooms are experiencing a surge in popularity as their health and wellness benefits become increasingly well-known. Driven by multiple intersecting trends, this popularity is directly reflected in the market performance and outlook for functional mushroom products.

Gaining a deeper understanding of the market data and the progression of the functional mushroom industry can provide investors valuable insights into the opportunities in this emerging market.

Also known as adaptogenic or medicinal mushrooms, functional mushrooms are a subset of fungi valued for their potential health benefits. Whereas ordinary mushrooms provide good nutritional content, functional mushrooms contain a range of bioactive compounds, including beta-glucans, polysaccharides, triterpenoids and antioxidants. Owing to their therapeutic effects, functional mushrooms have a long history in herbal and traditional medicine.

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2024

The global pharmaceutical market reached a total value of US$1.6 trillion in 2023, according to Statista, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharma ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy portfolio

  • In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks 1

  • Endothelin A (ETA) receptor activation contributes to elevated proteinuria in IgAN 2-5 ; atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent proteinuria and preserve kidney function for a broad patient population 1

  • IgAN is a heterogeneous, progressive, rare kidney disease with a need for effective, targeted therapies 6,7 ; up to 30% of patients with persistent proteinuria (≥1 g/day) progress to kidney failure within 10 years 8

  • Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression

Novartis today presented results from a pre-specified interim analysis of the Phase III ALIGN study of atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, in patients with IgA nephropathy (IgAN) 1 . Patients treated with atrasentan, in addition to supportive care (maximally tolerated and stable dose of a renin-angiotensin system [RAS] inhibitor), achieved a 36.1% (p

Proteinuria reduction is a recognized surrogate marker correlating with delaying progression to kidney failure and has been used as an endpoint in IgAN clinical trials to support accelerated regulatory approvals 10 . US FDA submission for atrasentan in IgAN is on track for the first half of 2024.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Novartis presents latest Phase III Fabhalta® data in C3 glomerulopathy showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

  • Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo 1 ; additional 6-month open-label data to be presented at a future medical meeting 2,3

  • Fabhalta showed a favorable safety profile with no new safety signals 1

  • C3G, an ultra-rare kidney disease caused by alternative complement pathway overactivation, progresses to kidney failure in ∼50% of patients within 10 years 4-7 ; currently there are no treatments approved for C3G 7-9

  • Fabhalta, an oral Factor B inhibitor of the alternative complement pathway, selectively targets the underlying cause of C3G 1 ; late-stage development program ongoing across several other rare diseases 10-13

Novartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta ® (iptacopan) at the late-breaking clinical trials session of the European Renal Association (ERA) Congress 1 . Patients treated with Fabhalta in addition to supportive care achieved a 35.1% (p=0.0014) reduction in proteinuria (as measured by 24-hour urine protein to creatinine ratio [UPCR]) at 6 months when compared to placebo on top of supportive care 1 . In many kidney diseases, proteinuria reduction is an increasingly recognized surrogate marker correlating with delaying progression to kidney failure 14,15 .

Fabhalta is an oral Factor B inhibitor of the alternative complement pathway being investigated in adult patients with C3 glomerulopathy (C3G) 1-3 . Regulatory submissions, including to the FDA and EMA, for the adult C3G indication are planned for the second half of 2024.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Logistics management concept.

The Business Case for Vertical Integration

Business models and go-to-market strategies are important elements of any investment decision.

In that regard, a vertically integrated business model offers several unique advantages over traditional business models, including enhanced resilience and access to multiple revenue streams across the value chain.

Understanding vertically integrated business models can help investors evaluate investment opportunities, particularly in new and emerging market segments.

Keep reading...Show less

Latest Press Releases

Related News

×